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First discovered in a light-sensitive retinal mutant of Drosophila, the transient receptor potential (TRP) superfamily of
non-selective cation channels serve as polymodal cellular sensors that participate in diverse physiological processes
across the animal kingdom including the perception of light, temperature, pressure, and pain. TRPM3 belongs to
the melastatin sub-family of TRP channels and has been shown to function as a spontaneous calcium channel, with
permeability to other cations influenced by alternative splicing and/or non-canonical channel activity. Activators of
TRPM3 channels include the neurosteroid pregnenolone sulfate, calmodulin, phosphoinositides, and heat, whereas
inhibitors include certain drugs, plant-derived metabolites, and G-protein subunits. Activation of TRPM3 channels at
the cell membrane elicits a signal transduction cascade of mitogen-activated kinases and stimulus response
transcription factors. The mammalian TRPM3 gene hosts a non-coding microRNA gene specifying miR-204 that
serves as both a tumor suppressor and a negative regulator of post-transcriptional gene expression during eye
development in vertebrates. Ocular co-expression of TRPM3 and miR-204 is upregulated by the paired box 6
transcription factor (PAX6) and mutations in all three corresponding genes underlie inherited forms of eye disease
in humans including early-onset cataract, retinal dystrophy, and coloboma. This review outlines the genomic and
functional complexity of the TRPM3_miR-204 locus in mammalian eye development and disease.
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Background
Discovery of the transient receptor potential (TRP) cation
channels traces back to visual function studies of the spon-
taneous, light-sensitive, retinal mutant strain (‘A-type’) of
Drosophila melanogaster in 1969 [1–4]. Electroretinogram
(ERG) recordings of these fruit fly mutants showed that
their photoreceptors exhibited a transient receptor poten-
tial that decayed to baseline rather than a sustained
plateau-like receptor potential characteristic of wild-type
fruit flies in response to prolonged bright light. Conse-
quently, the more aptly re-named trp mutant flies behaved
as if ‘blinded-by-light’ due to a proposed defect in the
phototransduction cascade rather than a failure of photo-
pigment regeneration [2]. Eventual recombinant DNA
cloning and sequencing of the trp ‘phototransduction’ gene
in 1989, identified a large (143 kDa) type-2 transmembrane
protein with 6–8 predicted transmembrane helices [5, 6]
that was later found to function as a light-activated calcium
ion (Ca2+) channel in 1992 [2–4, 7]. Simultaneously, a sec-
ond light-sensitive trp-like calmodulin-binding channel
(trpl) was discovered independently in Drosophila photore-
ceptors that likely accounted for the residual light response
(reduced quantum bumps) observed in the trp mutant [3,
8]. Despite discovery of a third trp homolog (trpγ) in Dros-
ophila retina [9], trp and trpl channels represent the
predominant light-activated channels in Drosophila photo-
receptors and trp became the founding member of the
TRP ion channel superfamily [10, 11].
Based on shared sequence homology with Drosophila trp,
the subsequent molecular cloning and sequencing of the
first human ‘canonical’ TRP channel (TRPC1) in 1995 [12,
13] has led to characterization of one of the largest ion
channel super-families in mammals composed of 28
members (27 in humans) that are sub-divided into six
sequence-related sub-families. These are named according
to structural and/or functional channel features to include,
ankyrin-repeat (TRPA1), canonical or classical (TRPC1-7,
human TRPC2 is a pseudogene), melastatin (TRPM1-8),
vanilloid-receptor (TRPV1-6), mucolipin (TRPML1-3), and
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polycystin (TRPP2, 3, 5) [14–16]. While all functional TRP
channels are cation permeable, they exhibit a wide range of
relative divalent and monovalent cation permeabilities (e.g.,
Ca2+, Na+, Zn2+, Mg2+) and gating mechanisms including
spontaneously active, voltage-gated, thermo-sensitive,
mechanosensitive, and ligand-gated channels. Indeed, many
TRP channels are polymodal responding to multiple phys-
ical and chemical stimuli and since they are widely
expressed in most, if not, all mammalian cell-types (e.g.,
neurons, nephrons) they participate in critical physiological
functions including the perception of light, temperature,
pressure, and pain [17–19]. Consequently, TRP channel
dysfunction has been associated with a variety of inherited
and acquired diseases in humans [20–22]. So far, mutations
in at least nine human TRP channel genes, across all six
sub-families, have been found to underlie over a dozen gen-
etic diseases, collectively referred to as ‘TRP channelopa-
thies,’ that affect multiple organs including the heart
(TRPM4), kidneys (TRPC6, TRPP1), skin (TRPV3), and
neuro-musculoskeletal system (TRPV4) [22–26].
Among the TRP channelopathies, mutations in the hu-
man genes for two closely related members of the melasta-
tin sub-family, TRPM1 and TRPM3, have recently been
linked with inherited eye diseases. TRPM1 (melastatin-1) is
the founder member of the melastatin sub-family of TRP
channels (TRPM1-8) that are numbered 1–8 in order of
discovery and classified into four phylogenetically con-
served groups: TRPM1/3, TRPM4/5, TRPM6/7, and
TRPM2/8 [27–29]. TRPM1 expression is associated with
terminal differentiation of pigmented neural crest-derived
cells or melanocytes, whereas loss of TRPM1 expression is
a diagnostic and prognostic marker for primary cutaneous
metastatic melanoma [30]. Further, expression of a non-
coding microRNA–miR-211—that is located within an in-
tron of the TRPM1 gene, is downregulated in metastatic
melanoma and miR-211 has been shown to function as a
tumor suppressor [30–32]. By contrast, disruption of
TRPM1 expression, by genomic insertion of a retroviral
long terminal repeat (LTR) sequence, has been found to
cause the Leopard (LP) complex spotting or white (unpig-
mented) coat pattern of certain horse breeds (e.g., Appa-
loosa). Homozygous LP horses also suffer from a retinal
disorder known as complete (no rod-photoreceptor func-
tion) congenital (present at birth) stationary (non-progres-
sive or stable) night-blindness (nyctalopia) or cCSNB [33].
Similarly, mutation or knockout (i.e., null) of the mouse
TRPM1 gene (Trpm1) results in a cCSNB-like phenotype
[34, 35]. Accordingly, over 50 coding mutations in the hu-
man TRPM1 gene (TRPM1) on chromosome 15q have
been shown to underlie autosomal-recessive forms of
cCSNB [36]. In addition, TRPM1 mutations (bi-allelic and
deletion) can present in childhood as progressive high-
myopia, involuntary eye movements (nystagmus, strabis-
mus, or squint), and an abnormal (electronegative) full-field
ERG with or without stationary or progressive night-
blindness [37]. However, unlike horses, abnormal skin pig-
mentation has not been associated with TRPM1 deficiency
or mutation in humans and mice [38, 39].
Despite its shared sequence homology with TRPM1 (~
69% amino acid similarity, 57% amino acid identity),
TRPM3 (melastatin-2) is not directly associated with mel-
anocyte differentiation or melanoma [30]. Rather, TRPM3
channel activity in vivo has been implicated in a variety of
neuronal and non-neuronal cellular processes. These in-
clude secretion of insulin by pancreatic β cells [40–42] and
hyaluronic-acid from synovial fibroblasts [43], glutamater-
gic transmission of cerebellar Purkinje cells [44], oligo-
dendrocyte maturation and CNS myelination [45], noxious
heat-sensing by dorsal root ganglia (DRG) neurons [46–
50], neuropeptide release and inflammatory pain [42],
mechanosensing in vascular smooth muscle cells [51] and
periodontal ligament cells during bone remodeling [52, 53],
and osmosensing hypotonic stress in ductus arteriosus con-
striction [54] and renal epithelial cells [55]. Further, TRPM3
channel activity has been shown to promote the growth of
clear cell renal cell carcinoma by stimulating oncogenic
(macro) autophagy dependent on microtubule-associated
protein 1 light chain 3α (LC3A) and LC3B [56].
In vitro functional expression studies have determined
that TRPM3 channels are activated by several structur-
ally unrelated agonists including (1) the endogenous ex-
citatory neurosteroid pregnenolone sulfate, which can
also weakly activate TRPM1 channels [51, 57–63]; (2)
cell-membrane phosphoinositol phosphates [64–66]; and
(3) noxious heat [46–50]. Conversely, they are inhibited
by (1) certain clinically approved drugs including non-
steroidal anti-inflammatory drugs (NSAIDs, e.g., mefe-
namic acid), antibiotics (e.g., voriconazole, which also
inhibits TRPM1 channels), sex-steroids (e.g., progester-
one), and synthetic drug-like antagonists [40, 41, 51, 61,
67–72]; (2) naturally occurring plant-derived secondary
metabolites (e.g., citrus flavanones) [73–75]; and (3) G-
protein coupled receptor βγ subunits [76–79]. By con-
trast, TRPM1 channels were found to be inhibited by
interaction with both Gα or Gβγ subunits [80].
Recent genetic studies have discovered that mutation
of the human TRPM3 gene underlies an inherited form
of early-onset or pediatric cataract with or without glau-
coma [81, 82]. Subsequently, mutation of the human
gene for microRNA-204 (miR-204) that is located within
an intron of the TRPM3 gene (reminiscent of TRPM1
and miR-211) has been shown to underlie an inherited
form of retinal dystrophy and ocular coloboma [83].
This gene-centric review focuses on the complex gen-
omic organization, sequence variation, transcriptional
regulation, and functional expression profile of the
TRPM3_miR-204 locus within the context of eye devel-
opment and disease.
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Review methodology
Comprehensive literature and bioinformatics searches
were conducted via the National Center for Biotechnology
Information (NCBI) website (www.ncbi.nlm.gov) through
December 2019. Keyword searches of PubMed yielded ap-
proximately 200 articles for TRPM3 and over 520 articles
for miR-204. Searches were refined by combination with
keywords for eye tissues (e.g., cornea(l), lens, ciliary body,
retina(l), optic nerve) and eye diseases (e.g., cataract, glau-
coma, retinoblastoma). Bioinformatics data was obtained
from several NCBI databases including Gene, Variation
Viewer, and Online Mendelian Inheritance in Man
(OMIM). Human and mouse bioinformatics data was de-
rived from the Genome Reference Consortium Human
Build 38 patch release 12 or 13 (GRCh38.p12/13) and the
Genome Reference Consortium Mouse Build 38 patch re-
lease 6 (GRCm38.p6), respectively. NCBI searches were
supported by comprehensive searches of other public bio-
informatics databases including BioGPS (www.biogps.org),
Ensemble Genome Browser (www.ensemble.org), Mouse
Genome Informatics (MGI) (www.informatics.jax.org),
and the University of California Santa Cruz (UCSC) Gen-
ome Browser (https://genome.ucsc.edu).
TRPM3_miR-204 gene organization and variation
Both the human and mouse TRPM3 genes host a micro-
RNA gene and exhibit extensive alternative splicing and
genetic variation.
Human TRPM3 gene
According to public genomic databases (e.g., National
Center for Biotechnology Information, NCBI, Genome
Reference Consortium Human Build 38 patch release 13,
GRCh38.p13), the human TRPM3 gene (TRPM3) is one
of the largest genes located on the long-arm of human
chromosome 9 (9q) spanning over 0.9Mb (Table 1). The
NCBI TRPM3 reference sequence (RefSeq) comprises at
least 30 exons that undergo extensive alternative splicing
to generate at least 23 alternative transcript variants (1–
23) encoding 23 predicted protein isoforms (a-w) (Supple-
mentary Table 1). The 23 RefSeq variants differ mainly in
usage of exons 1, 2, and 5 as translation start-sites and
usage of exons 4, 9, 16, and 18 that encode regions of the
amino (N) terminal TRPM domain (Fig. 1). Of the 23
RefSeq transcripts, the longest variant (16) encodes a pre-
dicted 1744 amino acid isoform (o) and the shortest vari-
ants (7, 8, 13, 22) encode isoforms of 230 (h) to 385 (l)
amino acids with the remainder ranging from 1184 (v) to
1719 (m) residues (Supplementary Table 1). Notably, the
short variants (7, 8, 13, 22) encode N-terminal short ‘cyto-
plasmic’ isoforms (h, c, l, u) that terminate in exon-10 and
do not encode the transmembrane channel region and
other carboxyl (C) terminal domains raising the possibility
of alternative non-channel functions.
In addition to the 23 validated RefSeq transcripts, there
are predicted to be at least 15 other TRPM3 transcript vari-
ants (Supplementary Table 1). These differ mostly from the
RefSeq transcripts either by inclusion of a non-coding exon
(11a) or by starting translation in exon-12 (X1-X7). The
predicted isoforms range from 410 (X8) to 1734 (X10)
amino acid residues and all but the shortest one (X8) har-
bor a transmembrane channel domain. Once validated,
TRPM3 may encode at least 38 transcript variants and
channel isoforms. In contrast to NCBI, the Ensemble gen-
ome browser currently supports 16 human TRPM3 tran-
scripts/isoforms with high confidence (www.ensemble.org).
According to the NCBI Variation Viewer (GRCh38.p12),
TRPM3 harbors over 220,391 single-nucleotide polymor-
phisms/variants (SNPs/SNVs) and over 2254 structural
variants including deletions (~ 4221), insertions (~ 1882),
and copy number variants (CNVs, ~ 974). The vast major-
ity of SNVs (> 92.3%) reside in the introns and flanking
untranslated regions (5′-UTR, 3′-UTR). Over 1600 coding
variants (cSNVs) have been reported in TRPM3. Most are
non-synonymous including missense (~ 1048), nonsense
(~ 43), splice-site (~ 43), and frameshift (~ 29) cSNVs of
unknown pathogenic significance and the remainder are
synonymous (~ 543) cSNVs (Table 1). While several non-
synonymous cSNVs are predicted in silico to be dam-
aging/pathogenic, so far only two missense mutations
(p.I65M, p.R1307T) in TRPM3 have been linked with
inherited forms of human cataract [81, 82]. In addition, a
SNV (rs9792446 G/A) located in intron-2 of TRPM3 has
been tentatively associated (p = 1.0e-7) with age-related
nuclear cataract in a cohort of 2265 twins (age ≥ 50).
Beyond eye disease however, TRPM3 variants have also
been associated with diverse phenotypic traits or diseases
in humans. Rare deletions involving coding exons of
TRPM3 have been documented in one case of Kabuki syn-
drome and in two brothers with autism [84, 85]. Common
non-coding SNVs in TRPM3 have been tentatively associ-
ated with longevity, elevated low-density lipoproteins and
triglycerides, systemic sclerosis, aspirin-exacerbated re-
spiratory disease, and thyroid nodules [86–90]. Coding
variants in TRPM3 (p.V83M, p.P937Q) have been specu-
lated to cause intellectual disability and epilepsy; however,
supporting functional expression studies were not per-
formed [91]. Finally, a TRPM3 gene variant (*T/C) has
been significantly associated with increased racing speed
in the whippet breed of dogs accounting for 11.6% of the
total variance in racing performance [92].
Mouse TRPM3 gene
The mouse TRPM3 gene (Trpm3) is located on murine
chromosome 19 and spans over 0.85 Mb comprising
some 32–33 exons that generate at least 30 RefSeq tran-
script variants (1–30) encoding 30 protein isoforms (a-
w, p, y, z, aa-dd) (Supplementary Table 2). Similar to
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TRPM3, alternative splicing mostly affects usage of
exons 1, 2, and 5 encoding the N-terminus; however,
there is currently no simple correlation between the hu-
man and mouse RefSeq transcript variants and channel
isoforms. Of the 30 mouse RefSeq transcripts, the lon-
gest variant (10) encodes a predicted 1744 amino acid
isoform (j) and the shortest variants (8, 9, 28–30) encode
isoforms of 234–265 amino-acids (h, i, bb-dd) with the
remainder ranging from 785 to 1734 residues (a-g, j-z,
aa) (Supplementary Table 2). Like TRPM3, the shortest
mouse RefSeq variants (8, 9, 28–30) encode N-terminal
short isoforms (h, i, bb-dd) that prematurely terminate
in exon-10 or exon-11 and do not encode the trans-
membrane channel region and other C-terminal do-
mains. Surprisingly however, two other short mouse
RefSeq variants are predicted to start translation in
exon-22 (two isoforms p encoded by variants 16 and 24)
or exon-26 (isoform aa) and encode all or part of the
transmembrane-channel region and other C-terminal
domains without the N-terminal domains.
In addition to the 30 mouse RefSeq transcripts/isoforms,
19 other Trpm3 transcript variants have been predicted
bringing the potential total of mouse TRPM3 isoforms to 49
(Supplementary Table 2). By contrast, the Ensemble genome
browser currently supports 24 mouse TRPM3 transcripts/
isoforms with high confidence (www.ensemble.org).
According to the Mouse Genome Informatics (MGI)
database (build 142), Trpm3 harbors over 13,646 validated
SNVs across some 56 strains of inbred mice (http://www.
informatics.jax.org/snp). The vast majority of Trpm3 SNVs
reside within introns (13,582, 99.5%) or mRNA UTRs (61).
Of 18 cSNVs, 17 are synonymous across 49 inbred strains
and only one (rs38720863 G/A) is non-synonymous in
three of 14 inbred strains. This non-synonymous cSNV is
predicted in silico to result in a conservative missense sub-
stitution (p.R1223H) with potentially damaging effects at
the protein level (PolyPhen-2 score = 0.997, SIFT score =
0.00). While no spontaneous Trpm3 mutant alleles or phe-
notypes have been documented, at least one targeted null
allele of Trpm3 has been reported [46] (Fig. 1). Trpm3-null
mice are viable and fertile; however, they display an im-
paired response to noxious heat [46, 49, 50] and an attenu-
ated pupillary light response [93].
MiR-204 gene
Both TRPM3 and Trpm3 harbor non-coding microRNA
genes that are co-transcribed in the same direction as
the host gene and participate in the post-transcriptional
regulation of gene expression. MIR204 (110 bp) is lo-
cated in intron-9 of TRPM3 on human chromosome 9
and Mir204 (68 bp) is located in intron-9 of Trpm3 on
mouse chromosome 19 (Table 1). MIR204 and Mir204
are highly conserved with identical seed regions required
for binding of the processed miR-204 (5p) product to
mRNA transcripts of target genes that include TRPM3
and Trpm3, respectively [56] (Fig. 2). Notably, miR-204
and miR-211, which is located within an intron of the
TRPM1 gene, share the same seed region and have been
classified as one microRNA family with the same set of
predicted target genes [94] (www.targetscan.org).
The NCBI Variation Viewer lists 180 variants in
MIR204 including CNVs (~ 97) and SNVs (~ 48),
whereas the MGI database lists 37 SNVs in Mir204
across 19 inbred mouse strains. One MIR204 SNV
(rs767146880) that lies within the seed region (n.37C>T)
has been linked with inherited retinal dystrophy and iris
Fig. 1 TRPM3_miR-204 gene organization and protein coding domains. Schematic of the human TRPM3 gene (TRPM3) coding for RefSeq
transcript-variant 9 and channel-isoform k. The non-coding miR-204 gene (MIR204) is located in intron-9 of TRPM3. Exons are indicated by
numbered boxes (1–30). Codon numbers are shown below each coding exon (exons 3, 9, 16, and 30 are skipped). ATG denotes alternative
translation start-sites. Asterisk denotes translation stop-site. Mutations in TRPM3 (exon 4 and 29) and MIR204 (intron 9) underlying human eye
disease are shown in red. The approximate locations of TRPM3 protein coding domains are indicated as follows. TRPM-start, consensus start of
the N-terminal TRPM homology domain (~ 700 amino acids). CaM/S100A1/PI(4,5)P2, calmodulin, S100A1 Ca2+-binding protein, and
phosphatidylinositol-4,5-biphosphate binding domains. CaM2–5, calmodulin binding domains 2–5. ICF, indispensable for channel function. S1-S4,
transmembrane segments 1–4, S5-P-S6, canonical pore flanked by transmembrane segments 5 and 6. TRP1–2, TRP box/motif 1 and 2. C-C, coiled-
coil domain. The insertion site of a gene-targeting construct (IRES-lacZ-neo) used to generate a null allele in the mouse TRPM3 gene (Trpm3) is
located in exon 20
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coloboma [83]. Recently, another SNV (rs718447 A/G)
flanking MIR204 upstream coupled with low expression
of miR-204 has been identified as a risk factor for poor
clinical outcome in acute myeloid leukemia [95] sup-
porting a role for miR-204 in tumor suppression [96].
TRPM3 channel structure-function domains
Like other TRP channels, TRPM3 channels share a pre-
dicted multi-pass (type-2) transmembrane topology, assem-
bled from tetramers of identical (homomeric) or similar
(heteromeric) TRP-subunits around a central pore, charac-
teristic of the voltage-gated ion channel superfamily [58, 97,
98]. In addition to forming homo-tetramers, TRPM3 and
TRPM1 subunits are believed to form heteromeric channels
[63]. Each TRPM3 subunit possess cytoplasmic amino- (N-)
and carboxy- (C-) terminal domains that flank the trans-
membrane (TM) domain containing six cell membrane-
spanning α-helices/α-helical segments (S1-S6) joined by
three extracellular and two intracellular loop regions. The
neurosteroid agonist pregnenolone sulfate (PS) is believed to
bind to a conserved stereo-specific (chiral) protein binding
site(s) (referred to as the ‘steroid modulatory domain’) that
likely resides within the four extracellular-transmembrane
regions of TRPM3 channels [40, 60, 61]. The TM domain
may be further sub-divided into two functional cation-
conducting pore domains. First, the central, canonical
cation-conducting pore of TRPM3-tetramers is formed by
α-helices S5 and S6 interconnected by the hydrophobic
pore-forming loop (P-loop) (Fig. 3). A polyclonal antibody
(TM3E3) directed against a conserved 14-amino acid
synthetic-peptide (L1030-N1043) located in the third extra-
cellular loop (E3) of TRPM3 has been reported to elicit spe-
cific but incomplete inhibition of recombinant hTRPM3
channel activation independent of the agonist used [99]
(Fig. 3). Second, the non-canonical cation-conducting pore
believed to be contained within the S1-S4 ‘bundle’ analogous
to the voltage-sensor domain (VSD) of voltage-gated K+,
Ca2+, and Na+ ion channels (Fig. 3). Like other TRPM chan-
nels, TRPM3 lacks the N-terminal ankyrin repeats, found in
the TRPA, TRPC, and TRPV sub-families, and instead dis-
play a unique, long N-terminal region of ~ 700 amino-acids
referred to as the TRPM homology domain that starts with
the consensus motif (W/F)IX3(F/L/I)CK(R/K)EC(V/I/
S)X12-24CXCG [98] (Fig. 3).
Multiple binding sites for the Ca2+-binding protein
calmodulin (CaM), which harbors 4-EF hand structures,
have been identified within the N-terminal TRPM hom-
ology region of TRPM3 [98, 100, 101]. Two N-terminal
regions of ~ 90 amino-acids, between A35-K124 and
H291-G382, in human TRPM3 have been experimentally
shown to bind both CaM and dimers of the structurally
similar S100 protein, S100A1, [100] (Fig. 3). In vitro mu-
tagenesis revealed that positively charged amino acids (K
and R residues) within these regions were critical for
CaM/S100A1 binding (Fig. 3). These CaM/S100A1 bind-
ing sites also serve as high-affinity binding sites for the
cell-membrane phosphatidylinositol phosphate (PIP),
phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) [102].
Up to five shorter CaM-binding sites (25 amino-acids/
residues) between K41-S65 (CaM1), Q193-G217
(CaM2), T301-N325 (CaM3), T577-G601 (Cam4), and
M769-K793 (CaM5) have been experimentally validated
in mouse TRPM3 (α2 isoform) [101]. Two of these
mouse TRPM3α2 CaM-binding sites (CaM1/K41-S65,
CaM3/T301-N325) overlap with the human TRPM3
CaM/S100A1-binding sites (Fig. 3). The mouse CaM2
and CaM3 binding sites are encoded by single coding
exons present in all TRPM3 isoforms, whereas, CaM1,
CaM4 and CaM5 binding sites overlap alternatively
spliced exons (Fig. 3, Supplementary Tables 1 and 2).
Further, the CaM3 and CaM4 binding sites overlap
pleckstrin homology (PH)-like domains containing a
consensus motif of positively charged (basic) amino-
acids—(K/R)-Xn-(K/R)-X-(K/R)2—that also serve as
Fig. 2 MiR-204 sequence, processing, and target sites. a Sequence alignment of human (MIR204) and mouse (Mir204) miR-204 genes. The 5p and
3p arms are shaded gray. The 7-nucleotide seed regions are underlined. Nucleotides critical for Drosha cleavage (C32, T92) and Dicer cleavage
(T54, G71) are shown in blue and green, respectively. The n.37C > T transition underlying RDICC is shown in red. b Precursor (pre)miR-204 stem
formation between the 5p and 3p arms. c Processed miR-204-5p aligned with binding sites in the mRNA 3′-untranslated regions (UTRs) of human
TRPM3 and mouse Trpm3. Asterisks (*) denote identical nucleotides. Colons (:) denote base pairing. Dashes (−) denote sequence gaps
Shiels Human Genomics            (2020) 14:7 Page 6 of 24
Fig. 3 (See legend on next page.)
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putative PI(4,5)P2 binding sites [103] (Fig. 3). Pull-down
assays revealed that CaM binding to TRPM3α2 was
Ca2+-dependent and in vitro mutagenesis studies deter-
mined that four positively charged lysine (K) residues
within CaM2 binding-site (Q193-G217) are critical for
both CaM binding and overall TRPM3 channel stability
[101]. A putative sixth CaM-binding site in TRPM3-α2
has been identified in silico, (P966-L987); however, this
site overlaps the S4 transmembrane domain and is likely
masked to CaM-binding during canonical pore opening
[101] (Fig. 3).
Toward the C-terminus, TRPM (and TRPC) sub-
family members contain a unique 23–25 amino acid
motif referred to as the TRP-domain, containing TRP-
box 1 (WKFQRY) and a proline-rich region referred to
as TRP-box 2 [18, 29]. The TRP-domain of TRPM3 also
contains a series of basic K/R residues (KFQRYQ-
LIMTFHER) similar to that required for PIP binding by
TRPM5 and TRPM8 [103, 104]. Further C-terminal to
the TRP-domain lies a conserved coiled-coil (CC) do-
main (R1219-T1271) (Fig. 3) harboring a heptad repeat
pattern of hydrophobic and polar or charged amino acid
residues that is believed to be sufficient for tetramer
self-assembly and necessary for channel function [29, 58,
105, 106]. However, TRPM3 (and TRPM1) lacks the C-
terminal enzyme domains found in the TRPM2 (pyro-
phosphatase), TRPM6 (kinase), and TRPM7 (kinase)
channels or so-called chanzymes [58, 107].
Canonical TRPM3 cation pore (S5-P-S6)
Functional expression studies in transfected cells (mostly
HEK293) or in cultured primary cells (e.g., β cells, neurons),
coupled with electrophysiological (e.g., patch-clamp) record-
ing and fluorometric Ca2+ imaging techniques have been
used to characterize the permeability and gating properties
of the central canonical TRPM3-cation pore ('alpha-pore')
in the absence or presence of known agonists including PS
and/or heat [47, 48, 50, 51, 57–62]. Two human kidney-
derived TRPM3 isoforms (hTRPM3_1555 and hTRPM3_
1325 amino-acids) were the first to be characterized as
spontaneously or constitutively active Ca2+ influx channels
located in the cell membrane and were inhibited, non-
specifically, by trivalent lanthanides La3+ and Gd3+ [108,
109]. Spontaneous Ca2+ influx by hTRPM3a_1555 was stim-
ulated by passively depleting Ca2+ stores with thapsigargan
or by activation of muscarinic receptors using carbachol
[108]. Constitutive Ca2+ influx by hTRPM3_1325 that was
activated by extracellular hypotonic stress (200 mOsmol)
caused cell swelling consistent with a role in cell volume-
regulation [109]. Similar overexpression studies subse-
quently confirmed that two alternatively spliced mouse brain
TRPM3 isoforms (mTRPM3α1 and mTRPM3α2) func-
tioned as spontaneous, weakly voltage-dependent, Ca2+ in-
flux channels with outwardly rectifying current-voltage (I-V)
relationships [110]. Significantly, these studies were the first
to reveal that alternative splicing of a 12-amino acid motif
(R1065-S1076) located within the canonical pore (P-loop)
region (Fig. 3) dramatically influenced permeability of
mTRPM3α1 and mTRPM3α2 to divalent cations (Ca2+ and
Mg2+) [110]. The ‘short-pore’ α2 isoform (lacking R1065-
S1076) was > 10-fold more permeable to Ca2+ and > 100-
fold more permeable to Mg2+ than the ‘long-pore’ α1 iso-
form (containing R1065-S1076). Additionally, extracellular
Na+ inhibited mTRPM3α2 channels but not mTRPM3α1
channels, whereas intracellular Mg2+ blocked both canonical
channels. In addition to Ca2+ and Mg2+, mTRPM3α2 chan-
nels were found to provide a regulated influx pathway for
Zn2+ ions in vitro [59]. By contrast, homomeric TRPM1
channels and heteromeric TRPM1/TRPM3 channels were
inhibited by extracellular Zn2+ in vitro [63, 111].
Subsequently, comparative expression of another mouse
brain splice-variant (mTRPM3α7) lacking an 18-amino acid
region (V512-T529) that lies N-terminal to the canonical
pore of mTRPM3α2, has led to the identification of a key
functional domain in TRPM3 [112]. Homomeric α7-
channels were non-functional and heteromeric α2/α7-
channels exhibited significantly reduced (> 70%) channel
number at the cell membrane and decreased agonist-
(See figure on previous page.)
Fig. 3 Amino acid alignment of human TRPM3 isoform-k (hK) and mouse TRPM3 isoform-w (mW). Partial amino acid alignments of mouse
TRPM3 isoform-d (mD, alias mα2) and isoform-a (mA, alias mα1) are included. Bars denote identical amino acids. Colons denote similar amino
acid changes. Single dots denote dissimilar amino acid changes. Dashes denote gaps. CaM1, first calmodulin binding-site in mD/mα2 (K41-P61,
shaded gray). Gray-shaded bars denote protein domains as follows. TRPM-start, consensus start-motif of the ~ 700 amino acid TRPM domain.
CaM2–5, calmodulin binding-sites 2–5 in hK, mW, and mD/mα2. An in silico CaM6 binding-site (P966-L987) overlapping S4 in mW is underlined.
CaM/S100A1 and PI(4,5)P2 binding-sites in hK (A35-K124, H291-G382) are also underlined. Putative PH-like domains and PI(4,5)P2 binding-sites
(K302-R311, K596-K611) in hK are shown in italics. ICF, indispensable for channel function domain (mD/α2), S1-S6, transmembrane α-helical
segments, P-loop, canonical pore-forming loop, TRP1–2, TRP-domain containing TRP-box 1 (1127-WKFQR-1132) and TRP-box 2 (1144-LPPPL-1148),
and C-C, coiled-coil domain (R1219-T1271). /\ indicates location of ‘long-pore’ region of mA/α1 that is absent in hK, mW, and mD/mα2.
Alternative methionine translation start-sites (M1, M65, M154), cataract-associated mutations (p.I65M, p.R1470T), and functionally important amino-
acids in the CaM/S100A1 binding-site (K45, R67, K71, R72), CaM2 binding-site (K198, K200, K205, K209), ICF domain (L516-Y525), S1 helix (Y976,
Y780, Y783), S3 helix (E939), S4 helix (W980, R983, D986, G989), and P-loop region (E1055) are shown in red font. A synthetic-peptide (L1030-
N1043) located in the third extracellular loop (P-loop) of hK used to raise a polyclonal antibody (TM3E3) is shaded gray. The C-terminal sequence
of the truncated hTRPM3–1325 isoform (hS) is indicated. Asterisks denote translation stop-sites
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induced Ca2+ influx compared to homomeric α2-channels.
Site-directed mutagenesis of this mTRPM3α2 sequence has
further defined a conserved, 10-amino acid, leucine-rich
domain (L518-Y527) that was indispensable for channel
function (ICF domain, Fig. 3) [112]. Consequently, the ICF
domain is believed to facilitate correct tertiary folding of
TRPM subunits and formation of functional homo-/hetero-
tetrameric TRPM channels [112]. Together, these studies
suggest that alternative splicing inside and outside the ca-
nonical TRP-pore region can directly influence TRPM3
channel permeability and that co-expression of channel-
negative or short ‘cytoplasmic’ isoforms may serve as
‘decoy-receptors’ to modulate or fine-tune full-length
TRPM3 channels [58, 98, 110, 112]. By analogy, short, cyto-
plasmic, N-terminal isoforms of TRPM1 (TRPM1-S) have
been proposed to interact with full-length TRPM1 isoforms
(TRPM1-L) in order to suppress channel activity of the lat-
ter by inhibiting its translocation to the plasma membrane
in vitro [113].
Non-canonical TRPM3 cation pore (S1–S4)
Recently, a second, distinct cation conductance pore has
been discovered in native mTRPM3α2 channels that is
analogous to the ‘gating-pore’ or ‘omega-pore’ associated
with artificial and disease-causing mutations in the
voltage-sensor domain (S4-helix) of classical voltage-
gated K+, Ca2+, and Na+ channels [42, 114–116]. Simul-
taneous opening of the canonical and non-canonical
pores was achieved by co-stimulation with PS and the
antifungal agent clotrimazole (Clt) or its structural ana-
logs (e.g., tamoxifen) or by administration of a synthetic
Clt-like ligand CIM0216 that represents the most potent
and specific agonist known for TRPM3 channels [42,
114]. In contrast to the canonical pore (S5-P-S6), activa-
tion of the non-canonical pore (S1–S4) resulted in dis-
tinct conductance and gating properties including (1)
induction of currents with an I-V relationship that recti-
fies in both inward and outward directions, with marked
inward currents at strong hyperpolarizing membrane po-
tentials; (2) a single-channel conductance of ~ 20 pS
(versus ~ 50 pS for canonical pore); (3) low Ca2+ high
Na+ permeability; and (4) resistance to Ca2+-dependent
de-sensitization and inhibition by La3+. Further support
for a non-canonical TRPM3 pore has been provided by
site-directed mutagenesis of functionally critical amino
acids in TRPM3 identified largely by homology modeling
with voltage-gated K+-channels. First, in vitro mutagen-
esis of a positively charged glutamate within the P-loop
region (E1057C) inhibited activation of the canonical
pore but not the non-canonical pore. Second, serial re-
placement of four amino acids (W982, R985, D988, or
G991) located within the S4-helix of mTRPM3α2 (Fig. 3)
inhibited activation of the non-canonical pore but not
the canonical pore [116]. Notably, these four TRPM3
residues aligned with the four positively charged arginine
residues (R1–R4) in the S4-helix of K+-channels that are
critical for voltage sensing. Third, serial neutralization of
three aromatic, tyrosine residues (Y878, Y882, Y885) lo-
cated in the S1-helix of mTRPM3α2 (Fig. 3), which are
believed to have proximity with W982 in the S4-helix,
resulted in non-canonical pore inhibition. Fourth, serial
neutralization of negatively charged residues (E941Q,
D964N) located in the S3-helix also inhibited activation
of the non-canonical pore. Altogether, these data point
to key roles for the S1, S3, and S4 α-helices in TRPM3
non-canonical pore formation. In particular, substitution
of larger, charged R residues with smaller, uncharged
amino acids (W, D and G) at the R1, R3, and R4 posi-
tions of the S4-helix in K+-channels appears to facilitate
non-canonical pore opening in TRPM3 channels.
TRPM3 channel signal transduction
Activation of TRPM3 channels at the cell membrane
(HEK293 cells) has been shown to trigger a Ca2+-
dependent intracellular signaling cascade of mitogen-
activated protein kinases (MAPKs) and several nuclear
phosphatases that regulate the stimulus response tran-
scription factors, including the activator protein-1 (AP-
1) transcription factor complex, resulting in altered gene
expression patterns (Fig. 4).
Kinases
PS-stimulation of recombinant hTRPM3 channel (1325
amino acids) Ca2+ influx results in activation (i.e., phos-
phorylation) of two key MAPKs that mediate signal trans-
duction from the cytoplasm to the nucleus/nuclear
transcription factors [117]. First, hTRPM3 Ca2+ influx acti-
vates extracellular signal-regulated protein kinase 1 (ERK1/
MAPK2) and 2 (ERK2/MAPK1) most likely via upstream
action of the protein kinase C (PKC) family of serine/threo-
nine protein kinases and the c-Raf proto-oncogene serine/
threonine-protein kinase (RAF1) or MAP kinase-kinase-
kinase (MAP3K) [117]. Second, an hTRPM3-mediated rise
in intracellular Ca2+ results in phosphorylation of c-Jun N-
terminal protein kinase 1 and 2 (JNK1/2) or MAPK8 and
MAPK9, respectively. In addition, hTRPM3 channel Ca2+
influx activated Ca2+/calmodulin-dependent protein kinase-
kinase-2 (CAMKK2) that in turn phospho-activated Ca2+/
calmodulin-dependent protein kinases (CAMKs) [56, 117].
Transcription factors
At least three transcription factors have been identified as
nuclear targets for phosphorylated forms of JNK1/2
(pJNK1/2) and ERK1/2 (pERK1/2) resulting from PS-
activation of hTRPM3 Ca2+ influx [117–120]. A key target
for pJNK1/2 is the basic-region leucine-zipper (bZip) tran-
scription factor c-Jun proto-oncogene (JUN)—a major com-
ponent of the AP-1 transcription factor complex. AP-1 is a
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collection of homo-dimers and hetero-dimers of the JUN, c-
Fos proto-oncogene (FOS), c-Maf proto-oncogene (MAF),
and activating transcription factor (ATF) sub-families of
bZip transcription factors that serves as an intersection
point for multiple intracellular signaling cascades involved
in the regulation of cell proliferation, transformation, differ-
entiation, and death in a tissue-specific manner [121]. For
pERK1/2, a key nuclear target is the erythroblast transform-
ation specific (ETS) domain-containing protein Elk-1
(ELK1) [122–124]. ELK1 belongs to the ternary complex
factor (TCF) sub-family of ETS transcription factors that in
complex with a dimer of the serum response factor (SRF)
interacts with the serum response element (SRE) to regulate
transcription of downstream target genes including the
zinc-finger transcription factor early growth response
protein-1 (EGR1) and FOS. In addition, pERK1/2 phosphor-
ylates the serine/threonine protein kinase salt-inducible
kinase-1 (SIK1) that in turn phosphorylates the bZip tran-
scription factor cAMP response element binding protein
(CREB) thereby activating downstream target genes of
CREB including FOS and possibly that for calcitonin; calci-
tonin gene-related peptide 1 (CGRP1). Ultimately, phospho-
activation of the stimulus response transcription factors,
AP-1 (JUN, FOS), CREB, ELK1, and EGR1, leads to upregu-
lation of mostly uncharacterized delayed response genes in-
cluding that for the inflammatory response chemokine
interleukin-8 (IL8) [125].
Phosphatases
At least two nuclear phosphatases have been implicated in
downregulating transcriptional activation resulting from PS-
stimulated hTRPM3 Ca2+ influx [117, 123]. First, hTRPM3
Ca2+ influx activates the MAP kinase or dual specificity
(tyrosine/threonine) phosphatase-1 (MKP1/DUSP1) that
negatively regulates the TRPM3 signaling cascade by de-
phosphorylating pERK2/MAPK1 and pJNK1/2. Second, the
Ca2+/calmodulin-dependent serine/threonine protein phos-
phatase calcineurin (CaN) inhibits the TRPM3 signaling cas-
cade by de-phosphorylating pELK1 [117, 123]. CaN is
composed of two polypeptides the protein phosphatase 3
catalytic subunit-alpha (PPP3CA) and the protein phosphat-
ase 3 regulatory subunit-beta (PPP3R1) and mutant forms
of both CaN subunits have been shown to inhibit AP-1 reg-
ulated transcription activated by hTRPM31325 Ca
2+ influx.
Fig. 4 Schematic summary of TRPM3 channel gating and signal transduction. Agonists PS or CIM0216 stimulate Ca2+ influx via the canonical
central pore (S5-P-S6) of TRPM3 homomeric tetramers ({}), whereas, mefenamic acid acts as an antagonist. Membrane phosphoinositides (PIPs)
enhance PS-activated TRPM3 Ca2+ influx. PS in combination with Clt, or CIM0216 by itself, can also stimulate Na+ influx via an alternative pore
opening ([]), distinct from the canonical TRP-pore. TRPM3 and TRPM1 monomers can also form heteromeric channels. TRPM3 channels are also
permeable to Zn2+ and Mg2+, whereas, Zn2+ inhibits TRPM1 channels. TRPM3-elevated intracellular Ca2+ phospho-activates cytoplasmic MAPK
signal transducers ERK1/2 and JNK1/2 that in turn phospho-activate nuclear transcription factors AP-1, ELK1, and CREB. Phosphatases CaN and
DUSP1 provide feed-back inhibition of TRPM3-dependent Ca2+ signaling by de-phosphorylation of transcription factor pELK1 and the MAPKs
pERK2 and pJNK1/2, respectively
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Overall, the concerted action of DUSP1 and CaN phospha-
tases acts as a negative feed-back loop for TRPM3-specific
Ca2+-dependent signal transduction.
In addition to PS, CIM0216-activation of hTRPM31325-
channel Ca2+ influx was also reported to activate AP-1 and
upregulate the transcriptional activation potential of JUN
and FOS [126]. Although CIM0216 was more potent than
PS at simulating hTRPM31325-channel Ca
2+ influx, it was
less effective (~ 50%) than PS at AP-1 activation and simi-
larly effective as PS in stimulating c-JUN and c-FOS,
whereas mefenamic acid from the fenamate class of
NSAIDs was completely inhibitory [118, 126]. Such tran-
scriptional activation and inhibition evoked by recombinant
hTRPM31325-channels in vitro appears to be physiologically
relevant since PS-stimulation of endogenous TRPM3 chan-
nels in rat insulinoma (INS-1) cells or primary mouse islet
cells also led to ERK1/2 activation and enhanced expression
of EGR1 and the AP-1 complex [127, 128].
Ocular expression and regulation of TRPM3_miR-
204
An expressed sequence tag (EST) for TRPM3 (alias
MLSN2) was first isolated from a post-mortem human
iris cDNA library and similar TRPM3 ESTs were found
in human lens, retina, and retinal pigment epithelium/
choroid cDNA libraries present in the NEIBank se-
quence database [129, 130] (https://neibank.nei.nih.gov).
Subsequent ocular expression of TRPM3 and/or its
hosted miR-204 have been detected, mostly by transcript
PCR amplification, in situ hybridization, or microarray
based techniques, in several human and mouse ocular
tissues, notably ocular epithelial cells (Supplementary
Table 3) (http://biogps.org). Currently, unbiased, high-
throughput RNA-sequencing techniques have begun to
provide more quantitative ocular expression profiles for
TRPM3 and miR-204 in human and mouse eye tissues
[131–134] (Supplementary Table 3).
Human TRPM3_MIR204
In the human eye, multiple RefSeq TRPM3 transcript
variants were present in the lens [81] and TRPM3 tran-
script levels in a human adult RPE cell line (ARPE-19)
approached those found in native RPE cells [135]. Re-
cently, TRPM3 has been immuno-localized to sub-
domains of the apical plasma membrane of human fetal
RPE cells with particular enrichment at apical tight junc-
tions and the base of primary cilia [136]. RNA sequen-
cing confirms that TRPM3 is more abundant in human
RPE tissue and cell lines and a lens stem cell line than in
retinal or corneal derived cells [137, 138].
MIR204 transcripts have been detected in the human
ciliary body, trabecular meshwork (HTM) cells, and in
lens epithelium and established human lens epithelial
cell lines (HLE-B3, SRA01/04) [83, 139–143]. MicroRNA
sequencing ranked miR-204 as the most abundant
miRNA in human ciliary body and the fourth most
abundant of the 11 miRNAs accounting for ~ 80% of
normalized reads collectively expressed in human ciliary
body, cornea, and trabecular meshwork—ocular tissues
involved in glaucoma and keratoconus [134]. In human
retina, miR-204 is expressed in the ganglion cell layer
(GCL), inner nuclear layer (INL), and outer nuclear layer
(ONL) along with the retinal pigment epithelium (RPE)
and the ARPE-19 cell line [83, 139, 144, 145]. Micro-
RNA sequencing analysis ranked miR-204 as the fifth
most highly expressed miRNA in human retina and the
most abundant miRNA in human RPE/choroid [133].
Mouse Trpm3_Mir204
In mouse anterior eye tissues, Trpm3 transcripts are
expressed in ciliary body and lens epithelium [93, 146, 147]
and in mouse lens epithelial cell lines [148, 149]. RNA se-
quencing established that Trpm3 transcripts were enriched
in the mouse lens during embryonic development (E10.5-
E16.5) [150]. In mouse retina, Trpm3 transcripts are
expressed in the optic-cup during eye development and in
mature retina Trpm3 transcripts are present in sub-
populations of cells in the GCL (Muller cell end-feet) and
INL (Muller cell bodies), and in the RPE and optic nerve
head (ONH) [93, 147, 151, 152]. TRPM3 was also strongly
immuno-localized to the inner plexiform layer (IPL) and a
subset (~ 40%) of cells in the GCL with weak immuno-
labeling of the INL and outer plexiform layer (OPL) of
mouse retina [153]. Quantitative PCR revealed that Trpm3
transcripts represented the second most abundant Trpm
transcript in mouse optic nerve head (ONH), whereas
qPCR and immuno-localization ranked TRPM3 channels
as the main TRP channel in optic nerve glial cells (astro-
cytes and oligodendrocytes) [152, 154].
Mir204 transcripts have been localized to mouse cil-
iary body non-pigmented epithelium, iris, lens epithe-
lium, and corneal epithelium [139, 155–158]. MicroRNA
sequencing ranked miR-204 as the second most abun-
dant miRNA (after miR-184) during lens development
(E15-P9) with miR-204-5p representing the dominant
form of processed miR-204 [132]. In mouse retina,
Mir204 transcripts are widely expressed in sub-
populations of cells in the GCL, particularly Muller glia,
INL, and in the RPE [93, 139, 146, 147, 151, 155–157,
159–163]. MicroRNA sequencing analysis ranks miR-
204 as the sixth most highly expressed miRNA in the
mouse retina and the fourth most abundant in the
mouse RPE/choroid [131].
Transcription factor regulation
Transcriptional regulation of TRPM3_miR-204 expression
has been directly linked with at least two transcription fac-
tors important for vertebrate eye development. In mice,
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Trpm3 and Mir204 were found to be co-regulated by the
paired-box 6 transcription factor, Pax6, during lens devel-
opment and an evolutionarily conserved mechanism has
been described in Japanese rice fish or medaka [164–167].
Disruption of Pax6 resulted in downregulation (> 2-fold) of
Trpm3 and Mir204 expression in the embryonic mutant
lens, optic cup, and iris/ciliary body progenitors, consistent
with direct Pax6 activation of Trpm3_Mir204 during eye
development. Chromatin immunoprecipitation (ChIP),
electrophoretic-mobility shift (EMSA), and reporter-gene
transfection assays combined with in silico predictions have
confirmed that Pax6 directly binds to 5′-regulatory se-
quences upstream of Trpm3 resulting in upregulation of
both Trpm3 and Mir204 transcripts [165–167].
In addition to Pax6, the microphthalmia/melanogene-
sis-associated transcription factor (MITF), which harbors
basic helix-loop-helix (bHLH) and basic-region leucine
zipper (b-Zip) ‘dimerization’ domains, has been implicated
in regulation of TRPM3_miR-204 and TRPM1_miR-211
[31, 32, 145]. In human fetal (hf) RPE cells, siRNA-
mediated knockdown of MITF resulted in downregulation
of TRPM3_MIR204 (and TRPM1_MIR211) along with
other RPE differentiation genes (e.g., TYR and TYRP1).
Conversely, co-transfection of MITF siRNA and pre-miR-
204/211 prevented hf-RPE de-differentiation consistent
with a critical role for MITF-mediated upregulation of
miR-204/-211 in directing hf-RPE differentiation [145].
Ocular function and dysfunction of TRPM3_miR-
204
The divergent roles of miR-204 and TRPM3 in ocular de-
velopment and disease, particularly of the lens and retina,
have begun to emerge from loss-of-function (knock-out/
down) or gain-of-function (e.g., overexpression) approaches
using several model organisms and cell-culture systems.
TRPM3_miR-204 in lens development and cataract
MiR-204 in lens development
An early indication that miR-204 was involved in eye de-
velopment emerged from studies of lens regeneration in
the Japanese newt [168]. Following lens removal in adult
newts, dorsal (but not ventral) iris pigment epithelial cells
transdifferentiate into lens-forming cells. Microarray ana-
lysis of this process revealed that miR-204 levels were up-
regulated (~ 2.7-fold) in the dorsal versus the ventral iris
consistent with differential regulation of miR-204 target
gene expression during lens development [168].
In medaka (Oryzias latipes, ola), miR-204 has been found
to be critical for lens development by modulating repres-
sion of the ‘three amino acid loop extension’ (TALE)
homeobox transcription factor myeloid ecotropic-viral inte-
gration site-1 homolog 2 or Meis2 [164]. Morpholino anti-
sense oligo-mediated knockdown of miR-204, by injection
of fertilized one-cell medaka embryos, resulted in a
morphant eye phenotype with incomplete penetrance char-
acterized by microphthalmia (≥ 60% penetrance) and lens
dysgenesis (in 90% of small eyes) [164]. Overexpression of
miR-204 double-stranded mimic (agomiR) in medaka em-
bryos also resulted in microphthalmia and lens dysgenesis
[164, 169]. At the transcript level, morpholino inactivation
of miR-204 resulted in abnormal activation of the transcrip-
tion factor Meis2, whereas overexpression of miR-204 re-
sulted in decreased Meis2 levels in medaka embryo eyes.
However, co-injection of a morpholino against Meis2 par-
tially rescued the morphant miR-204 eye phenotype,
whereas targeted disruption of miR-204-Meis2 interaction
resulted in a morphant miR-204-like eye phenotype. Meis2
was co-expressed with miR-204 in the medaka embryo lens
and peripheral optic cup and contains a phylogenetically
conserved 3′-UTR binding-site for miR-204 consistent with
a direct target gene for miR-204 repression. Furthermore,
Meis2 has been shown to directly activate Pax6 expression
during eye development in zebrafish, chick and mouse em-
bryos [164]. Taken overall, these data indicate that miR-204
suppression of the Meis2-Pax6 pathway participates in the
control of lens morphogenesis.
Beyond Meis2, a second target gene for miR-204 repres-
sion that encodes a member of the ankyrin repeat domain-
containing protein family Ankrd13a has been identified
during medaka lens development [170]. Morpholino knock-
down of miR-204 led to abnormal lens morphogenesis with
aberrant dorso-ventral organization of lens epithelium and
lens fiber cells and disorganized fiber cells at the center of
the lens vesicle. In addition, miR-204 inactivation caused
mesenchymal neural crest cell mislocalization, whereas
miR204 overexpression resulted in promotion of neural
crest cell and lens cell migration and elongation.
Knockdown of miR-204 in a human lens cell line
(H36CE) caused cell rounding accompanied by dramatic
cytoskeleton changes including actin disassembly, radial
distribution of microtubules, and increased focal adhesion
formation further supporting a role for miR-204 in cell mi-
gration/adhesion. In silico screening of predicted miR-204
target genes identified Ankrd13a as a strong candidate gene
that is expressed in the lens and predicted to interact with
actin-binding and focal adhesion proteins. At the transcript
level, morpholino knockdown of miR-204 resulted in up-
regulation of Ankrd13a, whereas overexpression of miR-
204 resulted in decreased Ankrd13a levels in medaka em-
bryo eyes. Ankrd13a was co-expressed with miR-204 in the
medaka embryo lens and migrating neural crest cells and
Ankrd13a harbored an evolutionarily conserved 3′-UTR
binding-site for miR-204 suggesting that it was a direct tar-
get gene for miR-204 repression. Furthermore, co-injection
of morphilinos against miR-204 and Ankrd13 largely res-
cued (> 80%) the abnormal lens fiber cell dysgenesis found
in the miR-204 morphant embryo but failed to rescue the
accompanying aberrant dorso-ventral polarity of the lens
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epithelium and fiber cells. These data suggest that Ankrd13
is part of a miR-204 repression network regulating verte-
brate lens morphogenesis [170].
In mice, miR-204 upregulation by Pax6 provides an im-
portant cue for lens development [165]. In silico analysis
of genes that were upregulated (> 1.5-fold) in mouse
lenses conditionally null for Pax6, revealed over-
representation of genes with conserved miR-204 binding
sites located in their 3′-UTR regions suggestive of good
candidates for miR-204 repression during lens develop-
ment. These predicted miR-204 target genes included a
member of the sex determining region Y (SRY)-related
high-mobility group (HMG) box family of transcription
factors—Sox11—that is required for neurogenesis and
ocular development along with several other genes in-
volved in cell migration/motility including those for un-
conventional myosin-X (Myo10) and fibrillin-2 (Fbn2).
Transfection studies confirmed that miR-204 bound to
the 3′-UTR of Sox11 transcripts and downregulated their
translation in mouse neuroblastoma (Neu-2a) and human
lens (H36CE) cell lines. In situ hybridization revealed that
Sox11 transcripts were elevated in conditional Pax6-null
mouse lenses consistent with Pax6 acting as an indirect
negative regulator of Sox11 expression via miR-204 re-
pression. Transfection studies also confirmed that Myo10
and Fbn2 were downregulated by overexpression of miR-
204 mimic and upregulated by miR-204 inhibitor. In me-
daka embryos, morpholino knockdown of miR-204 re-
sulted in upregulation (21–38%) of Sox11, Fbn2, and
Myo10 transcripts, whereas overexpression of miR-204
mimic drove downregulation (21–43%) of these tran-
scripts. Similarly, injection of medaka embryos with Pax6
transcripts significantly downregulated (43–56%) tran-
scripts for Sox11, Myo10, and Fbn2, whereas co-injection
of miR-204 morpholino resulted in partial recovery (18–
28%) of these transcript levels. Combined, these data dem-
onstrate that Pax6 simultaneously represses multiple
genes involved in neurogenesis (Sox11) and cell motility
(Myo10, Fbn2) through direct upregulation of Mir204
thereby promoting a non-neuronal lens epithelial cell fate
[165]. By extension, since miR-204 represses Meis2 ex-
pression in the medaka eye [164] and Meis1/2 regulates
Pax6 during mouse lens induction [164, 171], a negative
feedback loop between murine Meis1/2, Pax6, and
Mir204 has been proposed [165]. However, Meis1/2 ex-
pression is lost in the mouse lens by embryonic-day (E)
12.5, whereas Pax6 and Mir204 expression is retained
throughout eye development suggesting that such a nega-
tive feedback loop may be restricted to early lens placode
and/or vesicle formation [165].
MiR-204 in cataract
In addition to lens development, differential regulation of
miR-204 has been associated with loss of lens transparency
or cataract formation in humans and mice, including age-
related cataract, congenital cataract, diabetic cataract, and
secondary (post-surgical) cataract or posterior capsular opa-
cification (PCO)—a post-operative complication of cataract
surgery [172–177]. Microarray analysis has revealed down-
regulation (> 2-fold) of miR-204-5p and miR-204-3p in cen-
tral, anterior lens epithelium (capsulorrhexis) samples from
patients undergoing age-related cataract surgery [173, 175]
and miR-204-5p was one of the five most downregulated
(~ 60-fold) microRNAs in diabetic cataract [177]. Signifi-
cant downregulation of miR-204-5p (~ 67-fold) and miR-
204-3p (> 12-fold) has also been associated with the human
donor lens ‘capsular-bag’ model of PCO in vitro [176]. Ex-
perimental overexpression of miR-204-5p, by transfection
of primary lens epithelial cells (LECs) from the capsular-
bag PCO model, increased expression of the epithelial
marker, E-cadherin, and decreased expression of the
epithelial-to-mesenchymal transition (EMT) markers, alpha
smooth muscle actin (α-SMA), and vimentin. Further, miR-
204 overexpression was associated with enhanced repres-
sion of transforming growth factor beta-2 (TGFβ2)-induced
EMT by direct targeting of the DNA-binding protein
mothers against decapentaplegic homolog 4 (SMAD4)
[[176]]. Similarly, in a mouse lens capsular-bag model of
PCO, upregulation (> 2-fold) of miR-204 (by pre-miR-204
transfection) was associated with downregulation (15%) of
Meis, inhibition of LEC migration and expansion, and at-
tenuated expression of the EMT-marker, α-SMA [172].
These observations support a direct role for miR-204 in the
suppression of EMT by targeting of the TGF-β/SMAD sig-
naling pathway.
Besides EMT, miR-204 has been associated with differ-
ential regulation of oxidative stress-related genes in human
age-related cataract [175]. Microarray analysis of catarac-
tous lenses suggested that downregulation of miR-204 was
associated with a predominant up-regulation of pro-
oxidative genes (e.g., thioredoxin-interacting protein,
TXNIP), whereas similar numbers of anti-oxidative genes
were upregulated (e.g., glutathione peroxidase 1, GPX1) or
downregulated (e.g., aldehyde dehydrogenase 1A3,
ADH1A3). Remarkably, in silico analysis predicted that
miR-204 not only targeted the 3′-UTR of pro-oxidative
genes (e.g., TXNIP) for transcriptional repression but also
targeted the 5′-TATA-box promoter-sequence of anti-
oxidative genes (e.g., ALDH1A3) for transcriptional activa-
tion [175]. Thus, it was proposed that downregulation of
miR-204 caused inhibition of anti-oxidative genes and acti-
vation of pro-oxidative genes suggesting that a novel miR-
204-TATA box/3′-UTR gene-regulation network contrib-
utes to cataract pathogenesis [175].
In addition to age-related cataract and PCO, miR-204
was reported to be downregulated (> 4-fold) in central
anterior LEC samples from young children (1–4 years)
undergoing surgery for congenital (‘pulverulent’)
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cataract that typically presents at birth or during in-
fancy [174]. Transfection studies of a human LEC-line
(HLE-B3) and mouse capsular-bag LECs have further
revealed a negative correlation between miR-204 and
Meis2 transcript levels consistent with a role for miR-
204 regulation in lens development and congenital
cataract pathogenesis [174].
TRPM3 in cataract
The first unambiguous human disease association for
TRPM3 was discovered in a 5-generation Caucasian-
American family segregating pediatric cataract with
autosomal dominant transmission that mapped to
chromosome 9q [81]. Approximately 60% of individuals
affected with cataract were also diagnosed with high-
tension glaucoma (IOP > 30 mmHg) and anterior eye
defects including anterior segment mesenchymal dys-
genesis (ASMD), Haabs striae (horizontal breaks in
Descemet’s membrane in the cornea), megalocornea,
mild correctopia (pupil displacement), and persistent
pupillary membrane, suggesting that TRPM3 function
extends beyond the lens to the anterior segment (e.g.,
iris, cornea, and ciliary body). The underlying heterozy-
gous transition (c.195A>G) located in exon-4 of
TRPM3 (RefSeq variant-9) was not present in the Ex-
ome Aggregation Consortium (ExAC) database and was
predicted in silico to exert damaging effects on the
function of at least one channel isoform (RefSeq
isoform-k). Transfection studies of a recombinant
hTRPM3-GFP reporter construct harboring the human
cataract mutation have revealed that the Ile>Met sub-
stitution introduced an alternative translation start-site
located 89 codons upstream from the native methio-
nine found in at least eight other TRPM3 transcript
variants and channel isoforms (Refseq variants 1–8, iso-
forms a-h). Thus, in addition to damaging effects on
isoform-k function, the novel Ile>Met start-site may
exert deleterious effects on multiple RefSeq channel
isoforms by extending their N-termini with 89 novel
amino-acids. Recently, a second missense mutation
(c.3920G>C, p.Arg1307Thr) located in exon-29 of
TRPM3 has been discovered in a Chinese nuclear fam-
ily segregating pediatric cataract [82]. This heterozy-
gous G>C transversion was not present in the ExAC
database; however, in silico analysis (Polyphen-2 and
SIFT score) predicted that the non-conservative
p.Arg1307Thr substitution may be functionally benign
and has been designated as a variant of ‘uncertain sig-
nificance’ [82].
TRPM3_miR-204 in retinal development and disease
MiR-204 in retinal neurons
In medaka embryos, differential regulation of miR-204
has been directly implicated in retinal development [164,
169]. Beyond microphthalmia and lens dysgenesis, mor-
pholino knockdown of miR-204 resulted in aberrant
dorso-ventral patterning of the retina associated with
failed optic fissure closure or ventral coloboma with in-
complete penetrance (in 30% of small eyes) [164].
Knockdown of miR-204 resulted in upregulation of mul-
tiple putative target genes including several involved in
neurogenesis and axon guidance. For example, miR-204
repression resulted in upregulation of genes coding for
an ephrin ligand (ola-Efnb3) and an ephrin receptor
(ola-Ephb2) that was reversed by miR-204 overexpres-
sion during retinal development in medaka embryos.
Most miR-204 knockdown embryos (65%) displayed ret-
inal ganglion cell (RGC) axon pathfinding defects that
cause axons to invade other retinal layers rather than ex-
tend along the optic nerve fiber layer to vision centers in
the brain. Conversely, miR-204 overexpression resulted
in aberrant projection of axons to the contralateral optic
nerve and ectopic rostral projection of axons to the tel-
encephalon rather than the optic-tectum. Rescue of
these RGC axon misguidance defects was achieved by
co-injection of morpholinos for miR-204 and Ephb2 or
Efnb3 suggesting that miR-204 participates in RGC axon
growth and/or guidance, in part, by targeting the ephrin-
B receptor signaling pathway [169].
In mouse retinal neurons, miR-204 (and miR-211) has
been found to be reversibly up/downregulated during
light/dark adaptation independent of the circadian clock
[160]. During dark adaptation, miR-204 was downregu-
lated and upregulated during light adaptation as a result
of rapid miRNA decay and increased transcription (~ 2-
fold), respectively. Retinal Trpm3 transcript levels were
also upregulated, particularly in the INL, upon light ex-
posure. The physiological role of such light-induced
regulation in the inner retina is unclear. However, in the
case of miR-204, it has been speculated that high turn-
over facilitates assembly of new ribonucleoprotein com-
plexes termed miRNPs to cope with transcriptional
changes during neuronal activity [160].
MiR-204 in RPE
In human fetal (hf) RPE cells, the constitutively high
miR-204 levels (~ 10,000 copies/cell) have been func-
tionally linked with altered gene expression that main-
tains epithelial cell physiology [139]. First, miR-204
inhibition resulted in upregulation of target-genes in-
volved in TGF-β signaling (TGFBR2 and SNAI2) that
are known to promote EMT. Second, miR-204 inhib-
ition decreased (~ 80%) trans-epithelial electrical re-
sistance associated with reduced claudin gene
expression and tight-junction formation that is required
to maintain the epithelial barrier function of the RPE.
Third, miR-204 inhibition triggered apical membrane
hyper-polarization resulting from ion-channel activity
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(e.g., K+ channel) that is required for normal RPE-
photoreceptor interactions during the visual cycle. Thus,
as in the lens, miR-204 participates in preservation of the
epithelial cell phenotype of the RPE [139].
Prolonged culture (4 months) of confluent ARPE-19
cells resulted in massive upregulation (> 2000-fold) of
miR-204 (and miR-211) that was associated with differen-
tiation of a native RPE phenotype including a cobblestone
epithelial morphology and intense pigmentation [135].
Subsequent RNA-seq and qPCR confirmed that this dif-
ferentiated ARPE-19 phenotype was accompanied by
RPE-specific gene expression including genes involved in
melanogenesis (e.g., MITF, TYR, TRPM1) and 11-cis ret-
inal pigment regeneration in the visual cycle (e.g., RPE65,
RDH10) [135]. Strong upregulation of miR-204 (~ 13-fold)
accompanied trans-differentiation of RPE cells from a hu-
man parthenogenetic embryo stem cell (hPESCs) line
[178]. MiR-204 overexpression in transfected hPESCs re-
sulted in decreased levels of β-catenin interacting protein
1 (CTNNBIP1)—an inhibitor of the Wnt/β-catenin signal-
ing pathway. Reporter gene assays confirmed that
CTNNBIP1 is a direct target of miR-204 further support-
ing a role for miR-204 in modulating Wnt/β-catenin sig-
naling during RPE differentiation [178].
In developing mouse RPE, conditional loss of the
RNase III nuclease Dicer1, which cleaves pre-miRNAs,
resulted in significant depletion (~ 11-fold) of miR-204
along with upregulation of several predicted target genes
including Meis2 [162]. Dicer1-deficient RPE in vivo did
not exhibit overt changes in cell morphology, identity, or
fate (e.g., EMT) but, instead, was associated with in-
creased cell density, reduced cell size, and arrested de-
velopment of adjoining photoreceptors due to failed
assembly of outer segment disk membranes. These data
suggest that miR-204 supports RPE differentiation and
maturation of adjacent photoreceptors in vivo, especially
morphogenesis of the outer segments—a key structure
for phototransduction [162].
Recently, mice lacking miR-204 were found to develop
age-related (~ 9 months) RPE/retinal defects including
hyper-autofluorescent (white) deposits, abnormal light-
induced electrophysiological responses, increased micro-
glia migration to the RPE, and impaired phagocytosis of
photoreceptor outer segments accompanied by rhodop-
sin build-up in the RPE [179]. Further, knockdown of
miR-204 in primary cultures of human RPE resulted in
rhodopsin accumulation, elevated autophagy markers
(e.g., p62), increased autophagic vesicles, and decreased
lysosomes. Both miR-204-null mouse RPE and miR-204-
knockdown human RPE also exhibited increased expres-
sion of ras-related protein Rab22a, an inhibitor of
endosome maturation and a direct target of miR-204.
Together, these observations implicate miR-204 in
modulating the endolysosomal and/or autophagy
pathways to avoid pathogenic changes in the RPE/retina
that resemble those found in patients with age-related
macular degeneration (AMD) [179].
MiR-204 in glaucoma and retinoblastoma
Downregulation of miR-204 (~ 4-fold) has been reported
in a rat model of advanced glaucomatous retinal damage
experimentally induced by chronic elevation of intraocu-
lar pressure [180]. In particular, miR-204 was one of
eight downregulated miRNAs correlated with upregula-
tion of several validated and predicted target genes in-
volved in EMT and extracellular matrix (ECM)
remodeling further supporting a regulatory role for miR-
204 in modulating TGF-β signaling.
In a rat model of optic nerve crush injury, miR-204 up-
regulation in retinal blood vessels was accompanied by
decreased expression of growth-associated protein-43
(GAP-43) [181]. Similarly, GAP-43 expression was de-
creased in rats after ocular injection of miR-204 mimic,
whereas ocular injection of miR-204 inhibitor increased
GAP-43 expression. Increased TUNEL-positive retinal cell
death was also associated with optic nerve injury or miR-
204 overexpression suggesting that miR-204 promoted
apoptosis of retinal cells by inhibiting GAP-43 [181].
Downregulation of miR-204 (~ 2.5-fold) has been ob-
served in human retinoblastoma (RB) tissues and cell lines
when compared to normal pediatric retinas [182]. Restor-
ation of miR-204 levels inhibited RB cell migration and in-
vasion capability in vitro and decreased RB tumor growth
in vivo. RB miR-204 levels were inversely correlated with
those of cyclin D2 (CCND2) and matrix-metalloprotease-
9 (MMP9). Both CCND2 and MMP9 transcripts harbor
3′-UTR recognition sites for miR-204 suggesting that
miR-204 may play a tumor suppressor role in RB progres-
sion by targeting CCND2 and MMP9 [182].
MiR-204 in retinal dystrophy
In keeping with its role in vertebrate eye development, the
first identified mutation in MIR204 has been found to
underlie an inherited (autosomal dominant) pediatric
form of bilateral retinal (rod-cone) dystrophy and iris
coloboma with or without congenital cataract (RDICC,
OMIM 616722) segregating in a 5-generation British fam-
ily [83]. The causative heterozygous transition (n.37C>T)
was located within the phylogenetically conserved (7-nu-
cleotide) seed-region of MIR204 that is essential for
target-transcript recognition and downregulation (Fig. 2).
The n.37C>T point-mutation was not predicted in silico
to destabilize precursor (pre) miR-204 secondary structure
and did not significantly affect expression levels in trans-
fected cells of either mature, processed miR-204, or
premiR-204 suggesting that a loss-of-function or haplo-
insufficiency mechanism was not the underlying cause of
disease. Instead, functional overexpression in transfected
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ARPE-19 cells followed by RNA sequencing studies, re-
vealed that the mutant miR-204 targeted multiple novel
and aberrant mRNA transcripts and impaired recognition
of several authentic wild-type miR-204 targets consistent
with a deleterious gain-of-function mechanism. Overex-
pression of the n.37C>T mutant miR-204 by injection of
medaka fish embryos recapitulated (~ 90% penetrance) as-
pects of the human eye phenotype including coloboma
and increased photoreceptor (rod and cone), but not RPE,
TUNEL-positive cell death. Further, morpholino knock-
down of miR-204 in medaka retina resulted in a signifi-
cant reduction of the flash ERG b-wave amplitude
recorded under dim-light or scotopic (rod-photoreceptor
dominant) conditions. Combined these observations sug-
gest that, in addition to the adjacent RPE, miR-204 plays
an important role in photoreceptor differentiation, func-
tion, and survival in the outer retina [83].
TRPM3 in retina
Visual function testing has shown that loss of Trpm3
function in the mouse retina results in a relatively normal
ERG with negligible effects on either dim-light (scotopic)
or bright-light (photopic) ERG a-waves (photoreceptor-
derived) and ERG b-waves (OPL-derived Muller and ON-
bipolar cells) [153]. Thus, in contrast to TRPM1, TRPM3
appears to play a minimal role in visual processing by the
ON-bipolar cell pathway (IPL inner sub-lamina b activity)
that is activated (depolarized) by light exposure. However,
TRPM3 may function in regulation of the OFF-bipolar cell
pathway (IPL outer sub-lamina a activity), including OFF
ganglion cells accounting for ~ 40% of the GCL, that is
inhibited (hyperpolarized) by light exposure [153].
In contrast to Trpm1-null mice, which exhibited a pro-
found deficit in pupillary light reflex (PLR), Trpm3-null
mice displayed a more subtle attenuated PLR under both
bright light (rod/cone/melanopsin-response) and dim light
(rod/cone-response) conditions, consistent with a role in
non-image photoreception [93]. While Trpm3-null mice ex-
hibited rapid pupil constriction in response to bright light
that was maintained during illumination they failed to
achieve full pupil constriction (i.e., ~ 80% of wild-type). They
also displayed an abnormal post-illumination pupil response
with a more rapid pupil dilation compared to the sustained
post-stimulus pupil constriction of wild-type. In response to
dim light, pupil constriction in Trpm3-null mice was ap-
proximately 45% of that in wild-type. Muscarinic stimula-
tion of the eye by topical administration of the cholinergic
agonist, carbachol, resulted in complete pupil constriction
suggesting that the ciliary and iris-sphincter muscles were
not functionally impaired in Trpm3-null mice. Since
TRPM3 was not detected in outer retina photoreceptors
(rods and cones) or photosensitive (melanopsin-expressing)
retinal ganglion cells (pRGCs) of the inner retina, it was pro-
posed to play a more distal role in regulating pupillary
responses to light that may involve retinal Muller glial cells
and the ciliary body where TRPM3 was enriched [93].
In human RPE cells, the apical membrane co-
localization of TRPM3 and tight-junctions (ZO1) may
modulate junctional permeability and barrier function,
whereas TRPM3 enrichment at the base of the primary
cilium may contribute to sensing light-induced Ca2+
concentration changes in the sub-retinal space (or inter-
photoreceptor matrix) between the RPE and photorecep-
tors during the visual cycle [136]. Prolonged culture of
human ARPE-19 cells (4 months) resulted in upregula-
tion (3–4-fold) of TRPM3 (and TRPM1) transcripts to
levels approaching those of native human RPE cells
[135]. However, exposure of cultured ARPE-19 cells to
pro-inflammatory cytokines (e.g., IFN-y) resulted in
downregulation of TRPM3 (3–4-fold) and miR-204 (15–
95%) transcripts along with other genes indispensable
for RPE function, including MITF and TRPM1_MIR211
[183]. Since inflammation is believed to exacerbate
AMD pathogenesis, release of pro-inflammatory cyto-
kines from immune cells infiltrating the posterior eye
may trigger the RPE dysfunction implicated in AMD
[183].
TRPM3_miR-204 in cornea, trabecular meshwork, and
optic nerve
MiR-204 in corneal wound healing
Dramatic downregulation (> 200-fold) of miR-204 has been
detected during corneal wound healing following traumatic
corneal epithelial injury (by cell scraping) in mice [158].
Conversely, overexpression of miR-204 in transfected hu-
man corneal epithelial cells (HCECs) inhibited cell prolifera-
tion and migration by inducing cell cycle G1-arrest. These
findings suggest that miR-204 downregulation promotes
corneal epithelial wound healing following injury and that
miR-204 can be considered as a negative biomarker for cor-
neal wound healing response [158]. In broad support of this
premise, miR-204-5p was markedly upregulated (~ 5-fold)
in corneal epithelia of type-1 diabetic (Ins2Akita/+) mice
[184]. This miR-204 upregulation was correlated with
downregulation of the longevity gene coding for the NAD-
dependent protein deacetylase sirtuin-1 (SIRT1)—a
confirmed direct target for miR-204 [158, 184]. Under high
glucose conditions, miR-204 was increased in a mouse cor-
neal/limbal epithelium (TKE2) cell line, whereas SIRT1 and
the cell-cycle related gene coding for cyclin D1 (CCND1)
were downregulated inducing cell-cycle (S-phase) arrest.
However, antagomiR inhibition of miR-204 expression in
hyperglycemic TKE2 cells resulted in upregulation of SIRT1
and CCND1 expression accompanied by increased cell
growth and restored cell cycle progression. Further, sub-
conjunctival injection of miR-204 antagomiR promoted
corneal wound healing response in diabetic mice following
corneal epithelial injury. These data suggest that miR-204
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exerts a negative effect on corneal wound healing in diabetic
keratopathy by targeting SIRT1 thereby contributing to de-
layed progression of the epithelial cell cycle [184].
MiR-204 in corneal neovascularization
Loss of miR-204 expression (~ 20-fold) has been reported
in mice lacking Kelch-like Ect2-interacting protein
(KLEIP)—a genetic model of spontaneous corneal neovas-
cular dystrophy [185]. Such miR-204 downregulation in
late-stage Kleip-null corneas was correlated with strong up-
regulation of the proangiogenic factor angiopoietin-1
(ANGPT1) and its receptor tyrosine kinase (TIE2), but not
with canonical vascular endothelial growth factors A-C
(VEGFA-C). Bioinformatics analysis identified an miR-204
binding site in the ANGPT1 transcript and overexpression
of miR-204 mimic in transfected vascular endothelial cells
resulted in downregulation of ANGPT1 consistent with the
latter acting as a miR-204 target-gene and supporting a role
for the miR-204-Angpt1 pathway in Kleip-null corneal neo-
vascular dystrophy [185]. In addition, mice undergoing
suture-induced corneal neovascularization exhibited miR-
204 downregulation (~ 4-fold) that correlated with the
vascularized area of corneal epithelium [186]. Conversely,
sub-conjunctival injection of miR-204 agomiR inhibited
neovascularization after corneal injury and decreased ex-
pression of VEGFA and that of its receptor VEGFR2. Over-
expression of miR-204 agomiR also inhibited VEGFA
upregulation in primary corneal (limbal) epithelial cells
undergoing biomechanical stress in vitro and suppressed
proliferation, migration, and tube-formation in microvascu-
lar endothelial cell cultures—consistent with a role in inhib-
ition of corneal neovascularization [186]. Similarly, mice
subject to alkali-induced corneal neovascularization exhib-
ited downregulation of miR-204 (~ 10-fold) along with the
simultaneous upregulation of over 200 corneal genes pre-
dicted to be targets for miR-204 [187]. These upregulated
genes included several vasculogenic genes including that
for ANGPT1, which can activate the phosphatidylinositol-
3-kinase/AKT-serine/threonine kinase 1 (PI3K/AKT1)
pathway along with one of its down-stream targets VEGF.
Corneal delivery of miR-204, by recombinant adeno-
associated virus (rAAV) vector, normalized the expression
of multiple predicted target genes and pathways that were
upregulated by alkali-induced corneal injury [187]. Com-
bined, these observations suggest that miR-204 acts as an
endogenous suppressor of corneal neovascularization and
represents a potential therapeutic target for inhibiting cor-
neal angiogenesis.
MiR-204 in trabecular meshwork
Microarray and qPCR analyses have associated downreg-
ulation of miR-204 (~ 2.5-fold) with increased senes-
cence in primary cultures of human trabecular
meshwork (HTM) cells [141, 142]. Similar studies have
revealed that miR-204 overexpression in transfected pri-
mary HTM cells resulted in downregulation (> 1.5-fold)
of at least 12 genes with predicted and/or validated 3′-
UTR miR-204 binding-sites [143]. These downregulated
miR-204 target genes included inhibitors of apoptosis
(e.g., BCL2L2, BIRC2), activators of the endoplasmic
reticulum (ER)-stress response (e.g., HSPA5/BiP,
DDIT3/CHOP), and mediators of the inflammatory re-
sponse (e.g., IL8, IL11). When subject to oxidative-stress
(H2O2) or ER-stress (tunicamycin), HTM cells overex-
pressing miR-204-mimic displayed increased apoptotic
cell death, accumulation of oxidized protein (carbonyla-
tion) along with decreased expression of ER-stress
markers, and inflammatory factors [143]. Other miR-204
target genes downregulated in HTM cells overexpressing
miR-204 mimic include the fork-head box C1 transcrip-
tion factor (FOXC1)—a causative gene for anterior seg-
ment dysgenesis known as Axenfeld-Rieger syndrome
with a ~ 50% risk for high tension glaucoma—along with
several downstream FOXC1-target genes, notably MEIS2
[188]. Further, transfection studies have shown that
miR-204 mimic inhibited serum-induced contraction of
HTM cells cultured within collagen gels suggesting that
miR-204 participates in regulating trabecular meshwork
contractibility to modulate aqueous humor drainage and
intraocular pressure (IOP) in vivo [189]. Overall, these
data support a multi-functional role for miR-204 in
HTM cells and, more broadly, in anterior eye develop-
ment and disease.
TRPM3 in optic nerve
TRPM3 channels have been shown to participate in
replenishment of ER Ca2+ stores by store-operated
calcium entry (SOCE) and in sustainability of ATP-
mediated Ca2+ signaling in white matter glial cells
(astrocytes and oligodendrocytes) derived from mouse
optic nerve [154].
Conclusions
From ‘light-blindness’ in fruit flies (trp) to ‘night-blind-
ness’ in humans (TRPM1), TRP channels have been iden-
tified as evolutionarily important Ca2+ sensors in the
photosensitive retina [11, 36]. Recently, the TRPM3_miR-
204 locus has emerged as an important transcriptional
target for PAX6 that serves to highlight the complex con-
vergence of TRP channels and micro-RNAs with mamma-
lian eye development and disease [165]. In humans,
mutation of TRPM3 underlies pediatric cataract with or
without glaucoma and anterior segment defects, whereas
mutation of MIR204 underlies retinal dystrophy and iris
coloboma with or without cataract [81, 83]. Notably,
PAX6 mutations in humans also underlie a variable pan-
ocular phenotype(s) including aniridia (iris hypoplasia), fo-
veal hypoplasia, anterior segment dysgenesis 5 (ASD5),
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late-onset corneal dystrophy, ocular coloboma, and con-
genital cataract [190, 191]. Such overlap in eye disease
phenotypes supports a functional synergy between PAX6,
TRPM3, and miR-204 during eye development (Fig. 5).
Beyond genetic mutations, however, much remains to be
learned about the cellular and molecular mechanisms
underlying TRPM3_miR-204 function and dysfunction in
ocular gene expression and calcium dynamics.
MiR-204 and ocular gene expression
Mir-204 expression has been prominently associated with
development and differentiation of multiple eye tissues. In
the retina, differential regulation of miR-204 has been
linked with development of the neural retina that mediates
phototransduction, differentiation of the RPE that sup-
ports adjacent photoreceptor function and forms the outer
blood-retinal barrier of the eye, and with retinal disease.
First, miR-204 has been implicated in RGC axon guidance
to the visual cortex, in part, by targeting the Efnb2-Ephb2
pathway [164, 169]. Second, high levels of miR-204 has
been shown to preserve epithelial differentiation and bar-
rier function of the RPE to support photoreceptor func-
tion by targeting genes involved in EMT (e.g., TGFBR2)
and Wnt/β-catenin signaling (e.g., CTNNBIP1) [139, 178,
162]. Third, light-regulated changes in miR-204 transcrip-
tion and turnover may aid assembly of new miRNP com-
plexes required for transcriptional changes during
neuronal activity in the inner retina [160]. Fourth, lack of
miR-204 resulted in an age-related RPE/retinal (AMD-
like) phenotype associated with elevated Rab22a-mediated
inhibition of the endolysosome/autophagy pathways [179].
Fifth, mutation of miR-204 seed-region causes rod-cone
dystrophy associated with altered target gene expression
suggesting a key role for miR-204 in photoreceptor func-
tion and survival in the outer retina [83]. Sixth, miR-204
downregulation in glaucomatous retina was associated
with upregulation of genes involved in EMT and ECM-
remodeling suggesting that miR-204 may modulate
TGFβ-signaling [180, 181]. Seventh, miR-204 downregula-
tion in retinoblastoma suggested that it may act as a
tumor suppressor by targeting CCND2 and MMP9 [182].
Differential regulation of miR-204 expression has been
directly associated with development and differentiation of
the crystalline lens that facilitates fine-focusing of images
onto the retina and with clinically distinct types of cataract
formation. First, miR-204 controls lens morphogenesis, in
part, by targeting Meis2 and Ankrd13a [164, 170]. Second,
miR-204 upregulation by Pax6 drives lens epithelial cell fate
determination by targeting genes involved in neurogenesis
(e.g., Sox11) and cell motility (e.g., Myo10) [165]. Third,
miR-204 downregulation in age-related cataract and PCO
suggest that miR-204 targets genes involved in EMT (e.g.,
αSMA) and oxidative stress (e.g., ALDH1A3), whereas miR-
204 downregulation in congenital cataract implicated tar-
geting ofMeis2 [172–176].
Beyond retina and lens, differential regulation of miR-204
has been implicated in pathophysiology of the cornea that
generates most of the eye’s refractive/focusing power and
the trabecular meshwork that drains aqueous humor out-
flow from the anterior eye. First, miR-204 downregulation
promoted corneal epithelial wound healing, whereas miR-
204 upregulation inhibited wound healing in diabetic kera-
topathy by targeting SIRT1 and CCND1 to inhibit the cell
cycle [158, 184]. Second, miR-204 downregulation was asso-
ciated with corneal neovascularization after injury, whereas
miR-204 upregulation inhibited neovascularization by tar-
geting genes involved in vasculature formation (e.g., Angpt1)
[185–187]. Third, in trabecular meshwork cells, miR-
204 downregulation was associated with cellular aging,
whereas miR-204 upregulation targeted multiple genes
involved in apoptosis (BCL2L2), ER-stress (DDIT3/
CHOP), inflammatory response (IL8), and anterior eye
morphogenesis (FOXC1) [141–143, 188]. Fourth, miR-
204 upregulation inhibited the contractile ability of tra-
becular meshwork cells that is believed to modulate
aqueous fluid drainage and IOP [189].
Clearly, miR-204 plays complex multifunctional roles
in regulating ocular gene expression. While there is
some overlap of miR-204 target genes/pathways in dif-
ferent eye tissues (e.g., EMT in lens and RPE), so far
most miR-204 targets appear to be cell and/or disease
context dependent. However, despite its multiple target
Fig. 5 Schematic of PAX6 and TRPM3_MIR204 in human inherited eye disease
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genes, functional loss of miR-204 does not appear to
negatively impact eye development and differentiation in
mice that eventually acquire (~ 9 months) an AMD-like
phenotype [179]. Such sparing of eye development raises
the possibility of functional redundancy or compensation
between miR-204 and miR-211, which share the same
seed-region sequence and predicted target genes, and
provides a rationale for investigating the ocular pheno-
type of miR-204 and/or miR-211 null mice.
TRPM3 and ocular Ca2+ dynamics
TRPM3 is widely expressed in eye tissues and has been
tentatively implicated in both neuronal and epithelial cell
Ca2+ dynamics. In retinal neurons, TRPM3 has been pro-
posed to act as a Ca2+ sensor in the OFF-pathway of bipo-
lar cells and a subset of ganglion cells [153]. Similarly in
RPE, TRPM3 has been speculated to modulate tight-
junction permeability and to function as a Ca2+ sensor for
the sub-retinal space between the RPE and photoreceptors
during the visual pigment cycle [136]. TRPM3 channels
may also contribute to Ca2+ homeostasis (SOCE) in optic
nerve glial cells [154]. Functional loss of TRPM3 caused a
mild deficit in pupil (iris) constriction in response to light
that may involve retinal Muller glia and/or ciliary body
dysfunction [93].
In the lens, loss of TRPM3 has not been associated
with a cataract phenotype in mice, raising the possibility
of functional redundancy or compensation by other lens
TRP channels. For example, TRPV1 and TRPV4 have
been shown to participate in maintaining an intracellular
hydrostatic pressure gradient within the lens [192]. By
contrast, mutation of TRPM3 in humans underlies
pediatric cataract (with or without glaucoma and anter-
ior segment defects) suggesting a deleterious gain-of-
function mechanism that may compromise lens Ca2+
homeostasis [81]. Elevated cytoplasmic Ca2+—believed
to result from activation of a non-selective cation con-
ductance—has long been implicated in the pathophysi-
ology of lens aging and cataract formation in humans
and experimental animals [193]. Besides pediatric cata-
ract, TRPM3 channels may also contribute to the histor-
ically enigmatic non-selective cation current associated
with age-related cataract. Moreover, based on extraocu-
lar TRPM3 channel functions including secretion by
pancreatic β cells [40], mechano-sensing by vascular
smooth muscle cells [51] and osmo-sensing by renal epi-
thelial cells [55], it is conceivable that TRPM3 channels
participate in ocular epithelial cell volume regulation
and/or ion and fluid transport including aqueous humor
secretion by the ciliary epithelium that maintains IOP.
Further functional expression and disease-modeling
studies (e.g., CRISPR-Cas9 gene-editing) will be required
to elucidate the pathogenic effects of known and new-
found TRPM3 mutations on Ca2+ dynamics in the lens
and other anterior eye tissues including the ciliary body
and iris.
In addition to cellular aspects of TRPM3 channel func-
tion and dysfunction in the eye, several molecular aspects
warrant further investigation. First, since alternative spli-
cing can alter the functional properties of TRPM3 chan-
nels [110], the expression profile (i.e., exon usage) of
TRPM3 transcript variants and the functional properties
of corresponding TRPM3 isoforms in ocular tissues re-
quires further studies. In particular, how do short TRPM3
isoforms that lack transmembrane channel domains serve
to regulate full-length TRPM3 channels as proposed for
short and long TRPM1 channels [113]? Alternatively,
the short transcript variants of TRPM3 that all start
upstream (5′-) and end downstream (3′-) from miR-
204 may facilitate a transcriptional mechanism to in-
dependently regulate miR-204 and TRPM3 expres-
sion during eye development. Further molecular
investigations include characterization of ligand-
binding and heat-sensing domains in TRPM3 chan-
nels. Since PS is unlikely to cross the plasma mem-
brane due to its negatively charged sulfate side-
group, it is believed to bind a conserved stereo-
specific protein binding-site that likely resides within
the four extracellular-transmembrane regions of
TRPM3 channels [40, 47, 60, 61, 194]. By contrast,
CIM0216 is membrane permeable and activates
TRPM3 channels in a membrane-delimited manner
acting at sites both outside and inside the membrane
[42, 114]. In the case of heat-sensing domains, it is
notable that PS-activation of a truncated hTRPM3
channel (hTRPM31325) was not enhanced by heat
[68] raising the possibility that C-terminal sequences
may be involved in heat sensitivity. Other cytoplas-
mic sequences including those at the C-terminus
may also serve as interaction sites for TRPM3 chan-
nel inhibition by Gβγ sub-units [76–79].
Second, the true physiological agonists and antagonists for
TRPM3 channels in the eye remain elusive. The endogenous
neurosteroid, PS, is the most widely used experimental
agonist and it activates TRPM3 channels within physio-
logical concentration and temperature ranges suggesting
that integration of chemical and thermal stimuli to activate
cation conductance may be physiologically and/or pharma-
cologically relevant. Since heat (37 °C) sensitizes TRPM3
channels to activation by PS at levels close to those in blood
(1–5 μM range at birth, 100–150 nM range in adults), such
chemical-thermal synergy raises the possibility that circulat-
ing PS may act as an authentic agonist for TRPM3 channels
at body core temperature [57]. However, since TRPM3
channels are constitutively active (i.e., open), it is currently
unclear whether PS and other experimental agonists (e.g.,
CIM0216) actively open or gate the channels or simply
modulate the open-probability of already gated channels
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[58]. Intriguingly, PS has been implicated in decreasing IOP
and to be neuroprotective in a rat model of glaucoma [195].
These observations raise the possibility that TRPM3 chan-
nels may contribute to IOP homeostasis. Elevated IOP is a
major risk factor for glaucoma in humans and the majority
of family members segregating a cataract-causing mutation
in TRPM3 also developed high-tension glaucoma [81]. Sev-
eral experimental inhibitors of TRPM3 channels exhibit
strong anti-nociceptive properties (e.g., NSAIDs)—suggest-
ing a role for TRPM3 channels in ocular pain—while others
are dietary compounds (e.g., citrus flavanones) [71–74].
TRPM3 channel inhibition appears to be well tolerated, at
least in Trpm3-null mice, but may cause unwanted side ef-
fects in humans including reduced insulin secretion and/or
noxious heat insensitivity. However, none of the known
TRPM3 channel agonists or antagonists are likely to be spe-
cific enough for pharmacologic studies in vivo [58].
Finally, aside from physiological or pharmacological acti-
vation and inhibition, the constitutive intracellular regulation
and downstream signaling mechanisms of TRPM3 channels
in ocular tissues remain to be elucidated. Using transfected
(HEK293) cells, at least three intracellular mechanisms are
believed to regulate TRPM3 channels. CaM binding and
PIP hydrolysis serve as activators, whereas Gβγ-subunits act
as inhibitors [66, 79, 101]. Ca2+ influx from TRPM3 chan-
nels triggers a signaling cascade of MAPKs (e.g., ERK1/2)
and stimulus response transcription factors (e.g., AP-1) that
in turn alter expression of delayed response genes [123]. Al-
though HEK293 cells are derived from primary embryonic
human kidney and display an epithelial morphology, it is un-
clear that the same signaling pathways triggered by TRPM3
channels will be utilized in both ocular epithelia and ocular
neurons. Further, the identities of delayed response genes
targeted by TRPM3 channel signaling in ocular epithelia
and neurons remain to be discovered.
Future multidisciplinary studies including genomics,
transcriptomics, proteomics, and metabolomics of the
TRPM3_miR-204 locus will likely provide new insights
regarding ocular health and disease. Regardless of its
precise ocular function(s) however, the TRPM3 gene
along with that for miR-204 appear to have co-evolved
as a target locus for PAX6 to coordinate regulation of
gene expression with Ca2+ dynamics during vertebrate
eye development.
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